HIGHLIGHTS
- who: Soyoung Kim et al. from the Department of Physiology, College of Korean Medicine, Kyung Hee University, Kyungheedae-ro, Dongdaemun-gu, Seoul, Republic of Korea have published the research: Enhanced Therapeutic Effect of Optimized Melittin-dKLA, a Peptide Agent Targeting M2-like Tumor-Associated Macrophages in Triple-Negative Breast Cancer, in the Journal: (JOURNAL)
- what: To increase the stability of the peptide fragment was conjugated with PEGylation at the amino terminus and was named This final drug candidate was assessed in vivo in a murine TNBC model and showed superior effects on tumor growth survival . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.